Misplaced Pages

#804195

16-469: IFM may refer to: Organisations [ edit ] IFM Therapeutics , a US-based pharmaceutical company Institute of Fisheries Management , a UK non-profit organisation Institut Fizik Malaysia (Malaysian: 'Malaysian Physics Institute'), a Malaysian professional body Institute for Media and Communication Policy , a German research institution Intergalactic FM , an online radio station based in

32-488: A risk estimate Interaction-free measurement , in quantum mechanics Other [ edit ] Independent forest monitoring , in forest law enforcement International Formula Master , a form of Motor Racing IFM Investors , an Australian investment management company See also [ edit ] International Falcon Movement – Socialist Educational International , a federation of international progressive youth education organisations Topics referred to by

48-610: Is different from Wikidata All article disambiguation pages All disambiguation pages IFM Therapeutics IFM Therapeutics launched in 2015 in Cambridge, Massachusetts , based on seed funding from the Boston-based venture capital fund Atlas Venture . The company's founding involved seven people, a mix of executives and university professors. Series A financing was provided by Atlas, London-based Abingworth , and Swiss pharmaceutical company Novartis . The company

64-809: The common stock and common stock options issued to company founders, employees, friends and family and angel investors . Series A rounds are traditionally a critical stage in the funding of new companies. Series A investors typically purchase 10% to 30% of the company. The capital raised during a series A is usually intended to capitalize the company for 6 months to 2 years as it develops its products, performs initial marketing and branding, hires its initial employees, and otherwise undertakes early stage business operations. It may be followed by more rounds ( Series B, Series C, etc ). Because there are no public exchanges listing their securities, private companies meet venture capital firms and other private equity investors in several ways, including warm referrals from

80-533: The Netherlands Institut Français de la Mode (French: 'French Institute of Fashion'), a French higher-education institution iFM , Philippine radio network owned by Radio Mindanao Network Science and technology [ edit ] Immunofluorescence microscopy , a technique used for light microscopy Incremental funding methodology , an approach to software development Forest fire weather index , (French: indice forêt météo )

96-632: The United States, Series A preferred stock is the first round of stock offered during the seed or early stage round by a portfolio company to the venture capital investor. Series A preferred stock is often convertible into common stock in certain cases such as an initial public offering (IPO) or the sale of the company. Series A rounds in the United States venture capital community, particularly in Silicon Valley, are widely reported in business press, blogs , industry reports, and other media that cover

112-504: The company remained as a limited-liability company , from which it was anticipated further research spin-outs might take place. IFM Tre's leadership included Gary Glick and H. Martin Seidel, formerly of Novartis. An alternative view on the 2018, purchase by Bristol-Myers Squibb has characterized it as a straightforward acquisition of IFM, with remaining assets going to form IFM Therapeutics, which spawned two subsidiaries, IFM Tre and IFM Due,

128-508: The cost of business in fields such as software, data services, telecommunications, and so on. However, there are routinely series A rounds in excess of $ 10 million in fields such as pharmaceuticals , semiconductors , and real estate development . They all share a similar legal and financial framework, but specific terminology, deal terms, and investment practices vary according to business customs within different countries, business sectors, investor communities, and geographical regions. In

144-464: The investors' trusted sources and other business contacts; investor conferences and demo days where companies pitch directly to investor groups. As equity crowdfunding becomes more established, startups are increasingly raising their Series A round online using platforms like Onevest and SeedInvest in the US. These blended rounds include a mix of angel investors , strategic investors and customers alongside

160-479: The latter focused on development of cGAS/STING antagonists. IFM Tre was subsequently bought by Novartis in 2019. Gary Glick was tapped to be the company's chief executive officer during its initial formation. Glick founded a spin-out immunotherapy firm from the University of Michigan in 2006, Lycera, and served as the company's chief scientific officer until joining IFM. Two other C-suite members at

176-450: The offline venture capital investors. Smaller investment amounts are usually not worth the legal and financial expense, the burden on a company of adjusting its capital structure to serve new investors, and the analysis and due diligence on the part of institutional investors. A company that needs money for operations but is not yet ready for venture capital will typically seek angel capital . Larger amounts are usually unwarranted given

SECTION 10

#1732844907805

192-407: The other major venture capital firm supporting IFM. Series A round A series A is the name typically given to a company's first significant round of venture capital financing . It can be followed by the word round, investment or financing. The name refers to the class of preferred stock sold to investors in exchange for their investment. It is usually the first series of stock after

208-567: The outset were Dennis Dean, chief development officer , formerly of Vertex ; and Shomir Gosh, chief scientific officer, formerly of Tempero Pharmaceuticals. Gosh left IFM in 2018 for the post of chief scientific officer at the Harvard spin-out firm 28-7 Therapeutics. In 2017, Martin Seidel joined IFM as the head of R&D, coming from an executive position at Novartis. IFM's chairman was also an Atlas partner, Jean-François Formela, and an additional board member, Vincent Miles, came from Abingworth,

224-499: The payment—ten-times the Series A funding injection. The following year, in 2018, Boston-based IFM Tre formed with the spin-out of research and assets specifically related to blocking the NLRP3 complex, a so-called inflammasome . This spin-out, described as a subsidiary, subsequently secured funding from a familiar set of sources: Atlas, Abingworth, and Bristol-Myers Squibb. The rest of

240-510: The same term [REDACTED] This disambiguation page lists articles associated with the title IFM . If an internal link led you here, you may wish to change the link to point directly to the intended article. Retrieved from " https://en.wikipedia.org/w/index.php?title=IFM&oldid=1252461243 " Category : Disambiguation pages Hidden categories: Articles containing Malay (macrolanguage)-language text Articles containing French-language text Short description

256-463: Was originally formed with a dual development path, focusing on both autoimmune diseases and cancer immunotherapy . However, in 2017, the entire development program devoted to enhancing the body's innate immune response to cancer was purchased by Bristol-Myers Squibb , which set up a new company from this purchase and recruited IFM's CEO, Gary Glick, to head the new company. This purchase was notable in both its speed following IFM's establishment, and

#804195